medicare Drug Price Negotiations: What You Need to Know
For the first time, Medicare is directly negotiating the prices of certain prescription drugs, a landmark change stemming from the Inflation Reduction Act. This means potential savings for you and a shift in how pharmaceutical costs are managed within the Medicare system. I’ve been closely following thes developments,and here’s a breakdown of what’s happening and what it means for your healthcare.
The First Wave of Negotiated drugs
Recently, a second list of 15 drugs was announced for price negotiations, building on the initial 10 selected in 2024. These negotiations aim to lower costs for both you and Medicare, with the new prices taking effect in 2027. Here’s a look at the drugs included in this second round,along with their current costs and potential savings:
* Austedo (Teva): Currently $4,093,negotiated price $6,623.
* breo Ellipta (GSK): Currently $67, negotiated price $397.
* Xifaxan (Salix): Currently $1,000, negotiated price $2,696.
* Vraylar (AbbVie): Currently $770, negotiated price $1,376.
* Tradjenta (Boehringer Ingelheim): Currently $78, negotiated price $488.
* Janumet (Merck & Co.): Currently $80, negotiated price $526.
* Otezla (Amgen): Currently $1,650, negotiated price $4,722.
These figures represent the current average manufacturer price and the negotiated price Medicare has secured. You’ll begin to see these lower prices at the pharmacy in 2027.
Why These Drugs?
The drugs selected for negotiation meet specific criteria. Generally, they are “single-source” medications – meaning they don’t face competition from generic or biosimilar alternatives.This allows Medicare to focus on drugs where negotiation can have the most notable impact on costs.
Here’s a broader look at the types of conditions these drugs treat:
* Diabetes: Tradjenta and Janumet.
* Mental Health: Vraylar (depression).
* Autoimmune Conditions: Otezla (psoriasis).
* gastrointestinal Issues: Xifaxan.
* Neurological Conditions: Austedo (irregular body movements).
* Respiratory illnesses: Breo Ellipta.
How This impacts You
This is a significant step toward making prescription drugs more affordable for millions of Americans. Here’s what you can expect:
* lower Out-of-Pocket Costs: As prices decrease, your co-pays and overall drug costs could be reduced, especially if you rely on these medications.
* Expanded Access: Lower prices may make these medications accessible to more people who previously couldn’t afford them.
* Phased Implementation: Remember, the price reductions from the first round of negotiations will take effect in 2026, and these new negotiations will be implemented in 2027.
What’s on the Horizon?
The negotiations don’t stop here. In 2026, Medicare plans to negotiate prices for an additional 15 high-expenditure drugs. Importantly, this next phase will include both drugs administered by pharmacists (Part D) and those administered by physicians (Part B). This opens the door to negotiating prices for expensive biological drugs often delivered through infusions.
I’ve found that staying informed about these changes is crucial for navigating your healthcare costs. As Medicare continues to refine
Related reading